GlaxoSmithKline has been granted U.S. FDA approval for the world's first two-drug regimen to treat HIV.
The once-daily pill, Juluca, combines two previously approved drugs — dolutegravir and rilpivirine. The treatment is produced by ViiV Healthcare, a HIV specialist business majority-owned by GSK.
The current treatments for HIV involve combining three or four medicines and have multiple side effects. GSK and rival Gilead are both testing numerous simpler, more effective HIV treatments.
Read the Telegraph coverage